Biotech News

TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

Tarsus Pharmaceuticals (TARS)Tarsus Pharmaceuticals2026-06-25 13:46 ESTFDA / regulatory

IRVINE, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) today announced that a $15 million milestone payment due Tarsus has been achieved following regulatory approval of TP-03 (lotilaner ophthalmic solution) 0.25%, marketed as XDEMVY® in the U.S., by the

Open original release

Related news

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus and John Cena Partner to Raise Awareness of Demodex blepharitis, a Common Eyelid Disease Affecting Approximately 25 Million Americans

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus Reports First Quarter 2026 Financial Results and Recent Business Achievements

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus to Participate in Upcoming Investor Conference

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus to Participate in Upcoming Investor Conferences

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

TARSTarsus Pharmaceuticals2026-06-25 13:46 EST

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

View all latest news

Tarsus Pharmaceuticals

Tarsus Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

TARSZimmer Biomet2026-07-14 12:13 EST

Zimmer Biomet Names Chintan Desai President of Asia Pacific Region

TARSZimmer Biomet2026-07-13 12:14 EST

Zimmer Biomet Announces Webcast and Conference Call of Second Quarter 2026 Financial Results

TARSBMYBristol-Myers Squibb Company2026-07-13 10:59 EST

U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Mezigdomide in Patients with Relapsed or Refractory Multiple Myeloma

TARSGSK plc2026-07-13 07:00 EST

Jemperli (dostarlimab) achieves sustained clinical complete responses in dMMR/MSI-H locally advanced rectal cancer

TARSMerck2026-07-10 19:01 EST

FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)

Stock data

Close: 59.31 USD
Market cap: 2.54B USD
Exchange: NASDAQ
Sector: Biotechnology
Location: United States